Turbine's core technology, the Simulated Cell™ platform, uses machine learning to understand how human cells make decisions. The platform complexly models the molecular interactions in and around cells, enabling an amount of virtual experimentation nearly impossible in the physical world, revealing mechanisms that cause disease and response to treatment.
“It's clear that advanced technology and digital capabilities are major differentiators in the biopharmaceutical industry, and the future of drug discovery will be driven by AI,” said Tom Runivos, global lead at Accenture Ventures. Stated. “Turbine's AI-based platform has clearly demonstrated its ability to derive high-quality biological insights for clients across the biopharmaceutical industry.”
Turbine's platform is used by leading researchers to discover promising drug targets, select patient populations most likely to benefit from treatment, and identify combination therapy regimens that can increase treatment efficacy for specific patients. Verified with pharmaceutical companies. This allows Turbine to uncover otherwise hidden treatments and drugs that work in the lab but are likely to fail in clinical trials.
said Dr. Petra Janzer, senior managing director and global leader of Accenture's life sciences business. It could lead to the development of targeted therapies. Our investment reflects our commitment to support technology and digital capabilities that drive innovation in AI-based drug discovery, with the aim of delivering more effective treatments and enhancing patient care. doing. ”
“Because most unsolved complex diseases are heterogeneous, progress in leveraging AI for drug discovery is hampered by ethical and technical limitations in obtaining deep and diverse ground truth data. This gap To fill in, you need a toolkit that allows you to learn the basic rules of biology. in vitro Conduct experiments and apply them to patients you have never seen before. Turbine's Simulated Cells represent the heterogeneity of complex human diseases better than currently available wet lab experimental models, which are inherently biased towards representing specific disease types and have little scalability. can be designed on a large scale. ” said Szabolcs Nagy, co-founder and CEO of Turbine. . “By leveraging Accenture's expertise, we hope to expand our market reach and enhance our simulation platform to benefit the entire biopharmaceutical industry by ensuring the next experiment is always the right one. thinking about.”
Turbine is the latest company to join Accenture Ventures' Project Spotlight, an engagement and investment program focused on working with companies developing or applying disruptive enterprise technologies. Project Spotlight provides broad access to Accenture's expertise and its enterprise clients to help startups harness creativity and realize the promise of technology. Other digital simulation companies included in Project Spotlight include QuantHealth, Virtonomy, and Ocean Genomics.
Investment terms were not disclosed.
About Accenture
Accenture helps the world's leading businesses, governments, and other organizations build their digital cores, optimize operations, accelerate revenue growth, enhance citizen services, and create tangible value with speed and scale. We are the world's leading professional services company. We are a people and innovation-driven company with approximately 742,000 employees serving customers in more than 120 countries. Technology is at the core of today's change, and our strong ecosystem relationships make us one of the world's leaders in helping drive that change. We combine our strength in technology and leadership in cloud, data, and AI with unparalleled industry experience, functional expertise, and global distribution capabilities. Our wide range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song enable us to deliver unparalleled tangible results. These capabilities, along with our culture of shared success and 360-degree value creation commitment, enable us to help our clients reinvent and build trusted and lasting relationships. Our success is measured by the 360-degree value we create for our clients, each other, our shareholders, partners and communities. Visit www.accenture.com.
About turbines
Countless resources and time are spent around the world researching and advancing new treatments, which often end in clinical failure and do not benefit patients. A world in which the effects of any potential drug can be predicted on translatable biological models, including biological models that may not even be available to laboratory-based tests, while accurately representing a patient's biology. Imagine. At Turbine, we are disrupting the status quo by always striving to perform the right wet lab experiments.
Using machine learning to understand the decision-making logic of human cells, Turbine has built the world's first predictive simulation of patient biology. The Simulated Cell™ platform models the protein signaling that determines and drives cell fate. in silico We empower the biopharmaceutical industry by conducting experiments at scales not possible in the physical world and guiding experiments that identify and confirm disease-causing mechanisms.
Turbine's platform has been validated by leading pharmaceutical companies including AstraZeneca, Ono Pharmaceutical, Cancer Research Horizons, and Bayer. Additionally, Turbine has received funding from industry leaders including MSD (Merck & Co, Inc., Rahway, NJ, USA) Global Health Innovation Fund, Accel, and MassMutual Ventures.
For more information, visit www.turbine.ai or follow Turbine on LinkedIn.
# # #
contact address:
julie bennink
Accenture
+1 312 693 7301
julie.l.bennink@accenture.com
Balint Pahorczek
turbine
+36 30 675 7099
balint.paholcsek@turbine.ai
Copyright © 2024 Accenture. All rights reserved. Accenture and its logo are registered trademarks of his Accenture.
